Smart ring maker Oura files to go public

Oura confidentially filed a Form S-1 with the SEC, signaling plans for an IPO after raising $875 million at an $11 billion valuation in its last round. The Finnish smart ring maker said it has sold 5.5 million rings, up from 2.5 million a year earlier, and recently launched a proprietary AI model focused on women’s health. The filing underscores continued investor interest in wearable health tech and AI-enabled consumer products.

Analysis

Oura’s filing matters less as a standalone consumer IPO and more as a signal that “healthwear” is shifting from novelty to a platform category with recurring engagement and data monetization optionality. That is structurally negative for incumbents whose wearables are still primarily hardware-led: once a form factor proves it can sustain premium pricing, the battleground moves to software, retention, and proprietary health models rather than sensor specs. The second-order effect is that category leaders can compress the innovation cycle for Garmin- and Apple-like health features, forcing more spend on ecosystem lock-in just to defend share.

The key investment question is not whether another wearable can sell, but whether AI-driven health insights create a higher willingness to pay and lower churn than generic activity tracking. If Oura can convert women’s health into a differentiated use case, it raises the bar for any competitor trying to bundle similar features without a dedicated data moat. That is most relevant over the next 6-18 months, because product announcements and app-layer AI features typically matter more than the IPO itself in setting consumer expectations and pressuring incumbents’ roadmaps.

Consensus likely underestimates how little direct revenue exposure Garmin and Apple have to the ring form factor, but overestimates how insulated they are from narrative erosion. Even without immediate unit-share loss, a successful Oura listing can re-rate the market’s view of what “premium wearable” growth looks like and invite capital into adjacent private competitors. The more interesting risk is that public-market enthusiasm resets valuation benchmarks for the entire category, making it easier for another well-capitalized challenger to raise aggressively and attack the high-end health segment.

Key Decisions for Investors

• Short GRMN into any IPO-related wearable enthusiasm over the next 1-4 weeks; best risk/reward is a tactical trade because Garmin has the most direct narrative overlap and the least software optionality if premium health tracking becomes AI-led.
• Buy AAPL puts or put spreads 1-3 months out only on strength, not weakness; the thesis is not hardware displacement, but that investor expectations for differentiated health features rise faster than Apple’s cadence, compressing multiple if the market starts to price in slower services-driven wearables growth.
• Pair trade: long a private-market/consumer-tech beneficiary basket only if accessible via VC crossover or proxies; otherwise use long-health-software / short-hardware as the cleaner expression, since value migrates from device margin to data monetization.
• If you want to express a contrarian bullish view on incumbents, wait for post-IPO hype to fade and look for a better entry in AAPL on any pullback tied to wearable share fears; the market may overreact to niche form-factor competition given Apple’s ecosystem advantage.
• Set a 3-6 month catalyst calendar around Oura’s IPO pricing and initial product disclosures; if the company commands a premium software multiple, expect a follow-on read-through to other wearable/medical-data startups and a temporary underperformance window for GRMN.